Syngene International (NSE:SYNGENE) COGS-to-Revenue : 0.22 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Syngene International COGS-to-Revenue?

Syngene International's Cost of Goods Sold for the three months ended in Mar. 2024 was ₹2,028 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹9,169 Mil.

Syngene International's COGS to Revenue for the three months ended in Mar. 2024 was 0.22.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Syngene International's Gross Margin % for the three months ended in Mar. 2024 was 77.88%.

Syngene International COGS-to-Revenue Historical Data

The historical data trend for Syngene International's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syngene International COGS-to-Revenue Chart

Syngene International Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.25

0.30

0.27

Syngene International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.30	0.28	0.29	0.28	0.22

Syngene International COGS-to-Revenue Calculation

Syngene International's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	9302	/	34886
	=	0.27

Syngene International's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2028	/	9169
	=	0.22

Syngene International (NSE:SYNGENE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Syngene International's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2028 / 9169
	=	77.88 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Syngene International COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Syngene International's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Syngene International (NSE:SYNGENE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syngene International Ltd (NSE:SYNGENE) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

539268:India

Address

Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099

Website

https://www.syngeneintl.com

Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.

Syngene International (NSE:SYNGENE) Headlines

No Headlines